MetabolismNews.net

Metabolism Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Mediexplorer.it

Osteoporosis medications increase bone-mineral density ( BMD ) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy.Researchers ...


Low levels of total 25-Hydroxyvitamin D are common among black Americans. Vitamin D-binding protein ( DBP ) has not been considered in the assessment of vitamin D deficiency.In the Healthy Aging in Ne ...


Arena Pharmaceuticals has officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Belviq, a medicin ...


The risks of developing kidney failure and a calcium deficiency from osteoporosis drug Zoledronic acid ( Aclasta; Reclast ) are extremely rare, according to researchers at Loyola University Health Sys ...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Kynam ...


On 18 October 2012, the Committee for Medicinal Products for Human Use ( CHMP ) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Qsiva, int ...


New data have shown that Forteo ( Teriparatide; Forsteo ) significantly increased lumbar spine volumetric bone mineral density ( vBMD ) compared to Risedronate ( Actonel ) in men with glucocorticoid-i ...


Results from a prospective study have shown that patients with a body mass index ( BMI ) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with ...


Sanofi and Regeneron Pharmaceuticals have announced that the Phase 3 ODYSSEY MONO trial with Alirocumab, an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin/kexin ...


Merck ( MSD ) has announced that the HPS2-THRIVE ( Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events ) study of Tredaptive ( extended-release Niacin / Laropiprant ) ...


Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential immunogenicity of single and multiple escalating doses ( IV [ intravenous ] an ...


The results from a phase II trial for Odanacatib, a cathepsin K ( cat-K ) inhibitor in development for the treatment of osteoporosis in post-menopausal women, were presented at the 34th Annual Meeting ...


La Food and Drug Administration ( FDA ) has approved a new indication for Prolia ( Denosumab ) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the firs ...


The emerging idea that obesity may have an infectious origin gets new support in a cross-sectional study by University of California San Diego School of Medicine researchers who found that children ex ...


Home-based exercises followed by voluntary home training seem to be associated with long-term effects on balance and gait, and may help protect high-risk, elderly women from hip fractures, according t ...